These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 34160251)

  • 1. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth.
    Li Y; Bai H; Sanders-Buell E; Dussupt V; Townsley S; Donofrio G; Bose M; O'Sullivan AM; Kibuuka H; Maganga L; Nitayaphan S; Kosgei J; Pitisuttithum P; Rerks-Ngarm S; Eller LA; Michael NL; Robb ML; Ake J; Vasan S; Tovanabutra S; Krebs SJ; Rolland M
    J Virol; 2021 Aug; 95(17):e0079721. PubMed ID: 34160251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.
    Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Hunter E; Derdeyn CA
    PLoS Pathog; 2016 Nov; 12(11):e1005989. PubMed ID: 27851829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.
    Schorcht A; Cottrell CA; Pugach P; Ringe RP; Han AX; Allen JD; van den Kerkhof TLGM; Seabright GE; Schermer EE; Ketas TJ; Burger JA; van Schooten J; LaBranche CC; Ozorowski G; de Val N; Bader DLV; Schuitemaker H; Russell CA; Montefiori DC; van Gils MJ; Crispin M; Klasse PJ; Ward AB; Moore JP; Sanders RW
    J Virol; 2022 Jan; 96(1):e0155221. PubMed ID: 34669426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
    Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
    PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.
    Dubrovskaya V; Tran K; Ozorowski G; Guenaga J; Wilson R; Bale S; Cottrell CA; Turner HL; Seabright G; O'Dell S; Torres JL; Yang L; Feng Y; Leaman DP; Vázquez Bernat N; Liban T; Louder M; McKee K; Bailer RT; Movsesyan A; Doria-Rose NA; Pancera M; Karlsson Hedestam GB; Zwick MB; Crispin M; Mascola JR; Ward AB; Wyatt RT
    Immunity; 2019 Nov; 51(5):915-929.e7. PubMed ID: 31732167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.
    Hraber P; Korber BT; Lapedes AS; Bailer RT; Seaman MS; Gao H; Greene KM; McCutchan F; Williamson C; Kim JH; Tovanabutra S; Hahn BH; Swanstrom R; Thomson MM; Gao F; Harris L; Giorgi E; Hengartner N; Bhattacharya T; Mascola JR; Montefiori DC
    J Virol; 2014 Nov; 88(21):12623-43. PubMed ID: 25142591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.
    Schoofs T; Barnes CO; Suh-Toma N; Golijanin J; Schommers P; Gruell H; West AP; Bach F; Lee YE; Nogueira L; Georgiev IS; Bailer RT; Czartoski J; Mascola JR; Seaman MS; McElrath MJ; Doria-Rose NA; Klein F; Nussenzweig MC; Bjorkman PJ
    Immunity; 2019 Jun; 50(6):1513-1529.e9. PubMed ID: 31126879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.
    Ringe RP; Pugach P; Cottrell CA; LaBranche CC; Seabright GE; Ketas TJ; Ozorowski G; Kumar S; Schorcht A; van Gils MJ; Crispin M; Montefiori DC; Wilson IA; Ward AB; Sanders RW; Klasse PJ; Moore JP
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.
    Anthony C; York T; Bekker V; Matten D; Selhorst P; Ferreria RC; Garrett NJ; Karim SSA; Morris L; Wood NT; Moore PL; Williamson C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28679760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.
    Zhou T; Doria-Rose NA; Cheng C; Stewart-Jones GBE; Chuang GY; Chambers M; Druz A; Geng H; McKee K; Kwon YD; O'Dell S; Sastry M; Schmidt SD; Xu K; Chen L; Chen RE; Louder MK; Pancera M; Wanninger TG; Zhang B; Zheng A; Farney SK; Foulds KE; Georgiev IS; Joyce MG; Lemmin T; Narpala S; Rawi R; Soto C; Todd JP; Shen CH; Tsybovsky Y; Yang Y; Zhao P; Haynes BF; Stamatatos L; Tiemeyer M; Wells L; Scorpio DG; Shapiro L; McDermott AB; Mascola JR; Kwong PD
    Cell Rep; 2017 Apr; 19(4):719-732. PubMed ID: 28445724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth.
    Wagh K; Kreider EF; Li Y; Barbian HJ; Learn GH; Giorgi E; Hraber PT; Decker TG; Smith AG; Gondim MV; Gillis L; Wandzilak J; Chuang GY; Rawi R; Cai F; Pellegrino P; Williams I; Overbaugh J; Gao F; Kwong PD; Haynes BF; Shaw GM; Borrow P; Seaman MS; Hahn BH; Korber B
    Cell Rep; 2018 Oct; 25(4):893-908.e7. PubMed ID: 30355496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.
    Dubrovskaya V; Guenaga J; de Val N; Wilson R; Feng Y; Movsesyan A; Karlsson Hedestam GB; Ward AB; Wyatt RT
    PLoS Pathog; 2017 Sep; 13(9):e1006614. PubMed ID: 28902916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.